Biologically Active Small Molecules

PGF1&alpha-d4 contains 4 deuterium atoms at the 3, 3&#39, 4, and 4&#39 positions. It is intended for use as an internal standard for the quantification of PGF1&alpha by GC- or LC-mass spectrometry.

6-MNA is a competitive, non-selective COX inhibitor. The Ki values for ovine COX-1 and -2 are 21 and 19 &microM, respectively. The IC₅₀ values are 70 and 20 &microM for human recombinant COX-1 and -2, respectively.

6-MNA is a competitive, non-selective COX inhibitor. The Ki values for ovine COX-1 and -2 are 21 and 19 &microM, respectively. The IC₅₀ values are 70 and 20 &microM for human recombinant COX-1 and -2, respectively.

6-MNA is a competitive, non-selective COX inhibitor. The Ki values for ovine COX-1 and -2 are 21 and 19 &microM, respectively. The IC₅₀ values are 70 and 20 &microM for human recombinant COX-1 and -2, respectively.

6-MNA is a competitive, non-selective COX inhibitor. The Ki values for ovine COX-1 and -2 are 21 and 19 &microM, respectively. The IC₅₀ values are 70 and 20 &microM for human recombinant COX-1 and -2, respectively.

A natural ITC that has diverse effects on intracellular signaling, gene expression, and cell cycling in different types of cells in culture demonstrates neuroprotective effects in a mouse model of Parkinson&rsquos disease.

A natural ITC that has diverse effects on intracellular signaling, gene expression, and cell cycling in different types of cells in culture demonstrates neuroprotective effects in a mouse model of Parkinson&rsquos disease.

A natural ITC that has diverse effects on intracellular signaling, gene expression, and cell cycling in different types of cells in culture demonstrates neuroprotective effects in a mouse model of Parkinson&rsquos disease.

A natural ITC that has diverse effects on intracellular signaling, gene expression, and cell cycling in different types of cells in culture demonstrates neuroprotective effects in a mouse model of Parkinson&rsquos disease.

A synthetic agonist for GPR84 (EC₅₀ = 512 nM) promotes chemotaxis in human neutrophils (EC₅₀ = 318 nM) and amplifies TNF-&alpha production by LPS-treated U937 macrophages drives the recruitment of leukocytes and raises serum

A synthetic agonist for GPR84 (EC₅₀ = 512 nM) promotes chemotaxis in human neutrophils (EC₅₀ = 318 nM) and amplifies TNF-&alpha production by LPS-treated U937 macrophages drives the recruitment of leukocytes and raises serum

A synthetic agonist for GPR84 (EC₅₀ = 512 nM) promotes chemotaxis in human neutrophils (EC₅₀ = 318 nM) and amplifies TNF-&alpha production by LPS-treated U937 macrophages drives the recruitment of leukocytes and raises serum